Enlivex Therapeutics (NASDAQ: ENLV)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-19 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-07-15 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Enlivex Therapeutics (NASDAQ: ENLV) through any online brokerage.
There are no as such competitors for Enlivex Therapeutics.
The latest price target for Enlivex Therapeutics (NASDAQ: ENLV) was reported by HC Wainwright & Co. on Monday, May 2, 2022. The analyst firm set a price target for 15.00 expecting ENLV to rise to within 12 months (a possible 234.08% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Enlivex Therapeutics (NASDAQ: ENLV) is $4.49 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Enlivex Therapeutics.
Enlivex Therapeutics’s Q2 earnings are confirmed for Friday, August 19, 2022.
There is no upcoming split for Enlivex Therapeutics.
Enlivex Therapeutics is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.